Establishment Labs Hldgs Inc - ESTA STOCK NEWS

Establishment Labs Holdings (NASDAQ: ESTA) has released preliminary Q1 2025 results, expecting revenue of approximately $41.4 million, including $6.2 million from Motiva sales in the United States. The company maintains its 2025 revenue guidance of $205-210 million.

The US launch of Motiva is showing strong momentum, with March orders exceeding 100 per day. The company expects to achieve EBITDA positivity in 2025 and cash flow positivity in 2026, with anticipated tariffs having minimal impact (less than 50-basis points) on gross margins.

The company announced an upcoming investor day on June 12, 2025 in New York City, where leadership will present updates on the US Motiva launch, innovation roadmap, and financial outlook.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) presented 5-year follow-up data from the Motiva US IDE Study at The Aesthetic MEET 2025. The study, focusing on 451 primary augmentation patients, demonstrated high patient compliance at 88.5% after four years.

Dr. Caroline Glicksman, the Study's Medical Director, highlighted the consistently low complication rates, with no increase in capsular contracture or suspected/confirmed rupture cases since the two-year mark. The company received FDA approval for Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants for primary and revision breast augmentation on September 26, 2024.

Interim CEO Peter Caldini reported strong U.S. market momentum with over 800 accounts and more than 550 placing orders, representing a 20% increase from their previous update three weeks ago.

Establishment Labs (NASDAQ: ESTA) has announced a partnership with GRAMMY Award-winner Meghan Trainor, who recently underwent breast augmentation using Motiva Implants®. This partnership follows the US FDA approval of Motiva Implants® in October 2024.

The implants feature the patented SmoothSilk® surface technology, showing a low 0.5% capsular contracture rate and less than 1% device-related complications. Clinical studies report over 97% patient and surgeon satisfaction rates. The technology includes unique features like shape adaptation and enhanced biocompatibility.

Since 2010, over four million Motiva® devices have been delivered in more than 90 countries globally. The company's technologies are supported by over 200 patent applications and more than 100 clinical and scientific studies.

Establishment Labs (NASDAQ: ESTA) reported Q4 2024 financial results with revenue of $44.5 million, up from $31.6 million in Q4 2023. The company achieved a significant milestone with Motiva Implants' U.S. approval and launch, generating $3.3 million in U.S. revenue for Q4.

Q4 highlights include a reduced net loss of $18.7 million (15% improvement YoY) and adjusted EBITDA loss of $13.1 million (25% reduction YoY). The company maintains a strong cash position of $90.3 million, with access to an additional $25 million credit facility.

Management reaffirmed 2025 revenue guidance of $205-210 million, representing 23-26% growth over 2024, with expected U.S. sales of $35 million. The company projects Q1 2025 U.S. revenue of approximately $5.5 million and targets its first positive EBITDA quarter in 2025.

Establishment Labs Holdings (NASDAQ: ESTA), a global medical technology company focused on women's health in breast aesthetics and reconstruction, has announced its participation in TD Cowen's 45th Annual Health Care Conference. Founder and CEO Juan José Chacón-Quirós and CFO Raj Denhoy will present in a fireside chat on March 4, 2025 at 2:30 p.m. ET.

The presentation will be available via live webcast on the company's investor relations website, with archived versions accessible afterward. Establishment Labs offers solutions for breast health, aesthetics, and reconstruction in over 90 countries, having delivered more than four million Motiva devices since 2010.

The company's portfolio includes minimally invasive platforms such as Mia Femtech, Preservé, GEM (currently in pivotal study), Motiva Flora tissue expander, and Zensor RFID technology with the Zenº biosensor. These innovations are supported by over 200 patent applications and 100+ scientific studies, with manufacturing conducted at two FDA-compliant facilities in Costa Rica.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company focused on women's health and wellness in breast aesthetics and reconstruction, has announced its participation in Citi's 2025 Unplugged Medtech and Life Sciences Access Day. The company's leadership team, including CEO Juan José Chacón-Quirós, President Peter Caldini, and CFO Raj Denhoy, will present on February 27, 2025, at 8:00 a.m. ET.

The company has delivered over four million Motiva® devices to surgeons since 2010 and operates in more than 90 countries. Their product portfolio includes innovative solutions such as Mia Femtech®, Preservé™, GEM®, Motiva Flora® tissue expander, and Zensor™ RFID technology platform. These solutions are backed by over 200 patent applications and more than 100 scientific studies. Manufacturing takes place at two Costa Rica facilities compliant with ISO13485:2024 and FDA standards.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has launched Preservé™ in Brazil, marking the first country in its global rollout. Preservé is the company's second minimally invasive platform product, following Mia Femtech®. The technology is designed to preserve breast tissue during aesthetic breast surgery, maintaining structural anatomy and function for more natural outcomes compared to traditional augmentation.

Preservé combines proprietary minimally invasive surgical tools with Ergonomix2 implants featuring patented SmoothSilk® surface. It is intended for primary augmentations up to four cups, hybrid augmentations, and mastopexy augmentations. The launch took place at the Brazilian Breast Meeting in Rio de Janeiro with over 300 surgeons attending, featuring live surgery and academic sessions. Additional global launches are planned throughout the year, though the medical devices are not yet approved for commercial distribution in the United States.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company focused on women's health and breast aesthetics, will release its Q4 2024 financial results after market close on February 26, 2025. The company will host a conference call at 4:30 pm ET to discuss the results.

The company has delivered over four million Motiva® devices to surgeons since 2010 across 90+ countries. Their product portfolio includes Mia Femtech®, Preservé™ for breast augmentation, GEM® for gluteal modeling, Motiva Flora® tissue expander, and Zensor™ RFID technology platform. The company operates two FDA-compliant manufacturing facilities in Costa Rica and holds over 200 patent applications across 20 families, supported by 100+ scientific studies.

Establishment Labs Holdings (NASDAQ: ESTA) announced that CEO Juan José Chacón-Quirós will retire effective March 1, 2025, after 20 years of leadership. Peter Caldini, current President, will become Interim CEO. Chacón-Quirós will remain as a board member and advisor, focusing on expanding breast aesthetics markets and technology development.

The company also released preliminary unaudited results for fiscal year 2024, with expected revenue between $166.0-166.5 million. Fourth quarter revenue is anticipated to be $44.5-45.0 million, including approximately $3.2 million from Motiva sales in the United States.

Peter Caldini brings extensive experience from previous roles at Acreage Holdings, Pfizer Consumer Healthcare, and Bayer Consumer Healthcare. The company continues to focus on innovation, U.S. market leadership, and establishing minimally invasive breast aesthetics as an industry standard.